Thyrocare-Pharmeasy Deal - Impact On Traditional Diagnostic Models: Dolat Capital
A healthcare worker uses a pipette to process Covid-19 test samples in a laboratory (Photographer T. Narayan/Bloomberg)

Thyrocare-Pharmeasy Deal - Impact On Traditional Diagnostic Models: Dolat Capital

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

E-pharmacy chain, Pharmeasy, has agreed to buy 66% of promoter’s stake in Thyrocare Technologies Ltd. for Rs 45 billion.

The company will make an open offer for 26% subject to regulatory approvals.

The transaction is valuing the company at Rs 1,300/share, 14 times FY21 sales, 60 times profits and 40 times Ebitda.

The transaction is likely to strengthen Pharmeasy’s position as one of India’s largest digital healthcare brand with an integrated service platform between patient, doctor and medical retailers.

The integration will take 18-24 months for completion.

The deal is backed by well-known investors such as Temasek, B Capital, Kotak, etc.

Click on the attachment to read the full report:

Dolat Capital Pharmaeasy Acquires Thyrocare - Event Upate.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.